Exact Mass: 365.02768319999996
Exact Mass Matches: 365.02768319999996
Found 94 metabolites which its exact mass value is equals to given mass value 365.02768319999996,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Benzoylprop-ethyl
C18H17Cl2NO3 (365.05854320000003)
metolazone
C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators
indapamide
C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3822; ORIGINAL_PRECURSOR_SCAN_NO 3820 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3835; ORIGINAL_PRECURSOR_SCAN_NO 3834 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3799; ORIGINAL_PRECURSOR_SCAN_NO 3798 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3832; ORIGINAL_PRECURSOR_SCAN_NO 3829 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3815; ORIGINAL_PRECURSOR_SCAN_NO 3812 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3819; ORIGINAL_PRECURSOR_SCAN_NO 3817 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7807; ORIGINAL_PRECURSOR_SCAN_NO 7802 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7842; ORIGINAL_PRECURSOR_SCAN_NO 7839 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7849; ORIGINAL_PRECURSOR_SCAN_NO 7846 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7871; ORIGINAL_PRECURSOR_SCAN_NO 7868 CONFIDENCE standard compound; INTERNAL_ID 687; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7902; ORIGINAL_PRECURSOR_SCAN_NO 7900 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3686 CONFIDENCE standard compound; INTERNAL_ID 1111
Indapamide
Indapamide is only found in individuals that have used or taken this drug. It is a benzamide-sulfonamide-indole. It is called a thiazide-like diuretic but structure is different enough (lacking the thiazo-ring) so it is not clear that the mechanism is comparable. [PubChem]Indapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering the rapid component (IKr) or the inward rectifier current. Specifically it blocks or antagonizes the action the proteins KCNQ1 and KCNE1. Indapamide is also thought to stimulate the synthesis of the vasodilatory hypotensive prostaglandin PGE2. C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators
Metolazone
Metolazone is only found in individuals that have used or taken this drug. It is a quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. [PubChem]The actions of metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. Metolazone does not inhibit carbonic anhydrase. The antihypertensive mechanism of action of metolazone is not fully understood but is presumed to be related to its saluretic and diuretic properties. C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators
Fludarabine
C10H13FN5O7P (365.05366100000003)
Fludarabine is only found in individuals that have used or taken this drug. Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies. [Wikipedia]Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted. C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.
Nifursol
Veterinary antiprotozoal, especially for poultr
Fludara
C10H13FN5O7P (365.05366100000003)
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents
2-Hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid
p38 MAP Kinase Inhibitor
C20H13ClFN3O (365.07311300000003)
3-(1,3-benzothiazol-2-yl)-6-ethyl-4-oxo-4H-chromen-7-yl acetate
C20H15NO4S (365.0721750000001)
YK-4-279
C17H13Cl2NO4 (365.02215980000005)
Fludarabine phosphate
C10H13FN5O7P (365.05366100000003)
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.
Nifursol
C254 - Anti-Infective Agent > C258 - Antibiotic
tert-Butyl 4-(4-bromo-2-cyanophenyl)piperazine-1-carboxylate
C16H20BrN3O2 (365.07388000000003)
Zidapamide
C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic
S-1-Pyrrolidinecarboxylic acid, 2-(6-bromo-1H-benzimidazol-2-yl)-, 1,1-dimethyleth
C16H20BrN3O2 (365.07388000000003)
4-[BIS(4-FLUOROPHENYL)METHYLENE]PIPERIDINE HYDROBROMIDE
C18H18BrF2N (365.05905920000004)
1-(4-bromo-2-phenylmethoxyphenyl)-N-phenylmethanimine
Pyrido[1,2-a]benzimidazole, 1,2,3,4-tetrahydro- (6CI,7CI,8CI,9CI)
C18H11N3O4S (365.04702460000004)
Glucantime
P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01C - Agents against leishmaniasis and trypanosomiasis > P01CB - Antimony compounds D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents
3-BROMO-N-(3,3-DIETHOXY-PROPYL)-BENZENESULFONAMIDE
C13H20BrNO4S (365.0296340000001)
Bis(4-nitrophenyl) phosphorazidate
C12H8N5O7P (365.01613480000003)
5-(6-Bromonaphthalen-2-yl)-2,2-dimethyl-5-nitro-1,3-dioxane
C16H16BrNO4 (365.02626360000005)
6-BROMO-5-(2-FLUORO-4-NITROPHENOXY)-1-METHYL-1H-INDAZOLE
C14H9BrFN3O3 (364.98112760000004)
3-ETHYL-2-METHYL-5-PHENYL-BENZOOXAZOL-3-IUM IODIDE
Luxabendazole
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent
L-Cysteine,N-[(4-methylphenyl)sulfonyl]-S-(phenylmethyl)-
1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[[(trifluoromethyl)sulfonyl]oxy]-, phenylmethyl ester
3-(N-(4-CHLORO-3-METHYLISOXAZOL-5-YL)SULFAMOYL)-N-METHOXY-N-METHYLTHIOPHENE-2-CARBOXAMIDE
C11H12ClN3O5S2 (364.99068919999996)
N-((5-(4-chloroquinazolin-6-yl)furan-2-yl)Methyl)-2-(Methylsulfonyl)ethanamine
(2,3,4,5,6-pentafluorophenyl) 6-phenylpyridine-3-carboxylate
2-(2-Hydroxy-4-benzoyloxyphenyl)-5-chlorobenzotriazole
3-(2-CHLORO-6-FLUOROPHENYL)-N-(2-CHLORO-3-PYRIDINYL)-5-METHYL-4-ISOXAZOLECARBOXAMIDE
6-Chloro-3-indolyl β-D-glucuronide sodium salt
C14H13ClNNaO7 (365.02782179999997)
Itazigrel
C18H14F3NO2S (365.06973000000005)
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent C471 - Enzyme Inhibitor
Adenosine 5-monophosphate monohydrate
Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist. Adenosine 5'-monophosphate monohydrate has significant antiviral activity against HSV-1 and HSV-2. Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist. Adenosine 5'-monophosphate monohydrate has significant antiviral activity against HSV-1 and HSV-2. Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist. Adenosine 5'-monophosphate monohydrate has significant antiviral activity against HSV-1 and HSV-2. Adenosine 5'-monophosphate monohydrate is an adenosine A1 receptor agonist. Adenosine 5'-monophosphate monohydrate has significant antiviral activity against HSV-1 and HSV-2.
O,O-Diethylphosphoryl (Z)-2-(2-aminothiazol-4-yl)-2-acetyloxyiminoacetate
N-[4-(2,4-dichlorophenoxy)-6-(trifluoromethyl)-2-pyrimidinyl]-N-isopropylamine
C14H12Cl2F3N3O (365.03094780000004)
2-({[4-(Trifluoromethoxy)phenyl]sulfonyl}amino)ethyl Dihydrogen Phosphate
5-Monophosphate-9-beta-D-ribofuranosyl xanthine
C10H14N4O9P+ (365.04983840000006)
Orotidine 5-phosphate(3-)
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
8-Carboxy-2,4,6,9-tetrahydroxy-7-methyltetracen-5-olate
[(1S)-2-[2-[(2R)-2-amino-2-carboxyethyl]selanyl-1H-imidazol-5-yl]-1-carboxyethyl]-trimethylazanium
acetamidomethyl-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]oxyphosphinic acid
C8H17NO11P2 (365.02768319999996)
1-[4-(4-Bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide
C15H16BrN3OS (365.01973860000004)
4-Cyanobenzoic acid [4-oxo-6-[(2-pyrimidinylthio)methyl]-3-pyranyl] ester
C18H11N3O4S (365.04702460000004)
N-[3-(1,3-benzothiazol-2-yl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-2,2-difluoroacetamide
1-(3,4-Dichlorophenyl)-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea
tetracenomycin F1(1-)
A hydroxy monocarboxylic acid anion that is the conjugate base of tetracenomycin F1, obtained by deprotonation of the carboxy group.
2-(2-bromo-4-tert-butylphenoxy)-N-(2-furanylmethyl)acetamide
C17H20BrNO3 (365.0626470000001)
3-(benzenesulfonyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]propanamide
6-(2-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine
C20H16ClN3S (365.07534060000006)
N-[5-fluoro-2-(3-oxo-4H-quinoxalin-2-yl)phenyl]-2-thiophenecarboxamide
C19H12FN3O2S (365.06342240000004)
4-(2,3-Dihydro-1,4-benzodioxin-3-ylmethylamino)-3-nitrobenzenesulfonamide
C15H15N3O6S (365.06815300000005)
5-(3,4-Dimethoxyphenyl)-2-phenyl-4-thieno[2,3-d][1,3]oxazinone
C20H15NO4S (365.0721750000001)
5-(2,5-dichlorophenyl)-N-(2-propyl-5-tetrazolyl)-2-furancarboxamide
1-[(E)-[3-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methylideneamino]-3-ethylthiourea
C17H17ClFN3OS (365.07648340000003)
2-Phenylbutanoic acid [2-(3,5-dichloroanilino)-2-oxoethyl] ester
C18H17Cl2NO3 (365.05854320000003)
5-ethyl-N-[[2-(3-pyridinyl)-4-thiazolyl]methyl]-2-thiophenesulfonamide
2-(4-Bromo-3-methylphenyl)-4-[(3-methoxypropylamino)methylidene]-5-methyl-3-pyrazolone
C16H20BrN3O2 (365.07388000000003)
ethyl 2-{[(1E)-(4,6-dioxo-2-thioxohexahydropyrimidin-5-yl)methylene]amino}-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate
6-(3-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine
C20H16ClN3S (365.07534060000006)
2-(4-(Tert-butyl)benzamido)-4,5-dichlorobenzoic acid
C18H17Cl2NO3 (365.05854320000003)
1-(2-Furanylmethyl)-4-[oxo(thiophen-2-yl)methyl]-5-phenylpyrrolidine-2,3-dione
C20H15NO4S (365.0721750000001)
Methyl 2-O-chlorobenzoyl-4-chloro-N-methyloxalonilate
C17H13Cl2NO4 (365.02215980000005)
Orotidine 5-phosphate(3-)
Trianion of orotidine 5-phosphate arising from deprotonation of carboxylic acid and phosphate functions.
Afizagabar
C19H12FN3O2S (365.06342240000004)
Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the α5-GABAAR, with an IC50 of 585 nM for α5β2γ2 and a Ki of 66 nM for α5β3γ2. Afizagabar enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy[1].
BMS-986121
BMS-986121 is a positive allosteric modulator (PAM) of the μ opioid receptor extracted from patent WO2014107344. BMS-986121 is built on a chemical scaffold representing a new chemotype for μ receptor PAMs[1][2][3].
GYKI 52466 (dihydrochloride)
C17H17Cl2N3O2 (365.06977620000004)
GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research[1][2].
HIF-2α-IN-2
C17H13F2NO4S (365.05333220000006)
HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor extracted from patent WO2015035223A1, Compound 232, has an IC50 of 16 nM in scintillation proximity assay (SPA)[1].